Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma (IAC-RB)

NCT00857519 NA COMPLETED

Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased organ including the liver, brain, and eye. With focused chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it decreases the chance of toxicity to other organs such as bone marrow suppression (causing low blood counts) and the development of other cancers in the future.

Details

Lead sponsor	Wills Eye
Phase	NA
Status	COMPLETED
Enrolment	10
Start date	2009-01
Completion	2014-04

Conditions

• Retinoblastoma

Interventions

• Melphalan, Carboplatin

Primary outcomes

• Tumor control — after 5 cycles of chemotherapy

Countries

United States